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Objective:To determine the impact on late postoperative renal function of suprarenal and infrarenal fixation of endografts
used to treat infrarenal abdominal aortic aneurysm (AAA).
Methods: Retrospective analysis of 277 patients treated from 2000 to 2003 with three different endografts at two clinical
centers. Five patients on dialysis for preoperative chronic renal failure were excluded. Group IF of 135 patients treated
with an infrarenal device (Medtronic AneuRx) was compared with group SF of 137 patients treated with a suprarenal
device (106 Cook Zenith and 31 Medtronic Talent). Renal function was evaluated by calculating preoperative and latest
postoperative creatinine clearance (CrCl) using the Cockcroft formula. Patients who developed a >20% decrease in CrCl
were considered to have significantly impaired renal function.
Results: There were no significant differences in patient age, sex, aneurysm size, preoperative risk factors, dose of intra-
and postoperative contrast, or baseline CrCl (IF: 69.3 mL/min, SF: 71.7 mL/min, P  .4). Follow-up time of 12.2
months was the same in both groups. CrCl decreased significantly during the follow-up period in both groups (IF: 69.3
mL/min to 61.7 mL/min, P< .01; SF: 71.7 mL/min to 64.9 mL/min, P< .03). Postoperative CrCl (IF: 61.7 mL/min,
SF: 64.9 mL/min, P  .3), and the rate of CrCl decrease during the follow-up period (IF: 10.9%, SF: 9.5%, P  .2)
was not different between the two groups. The number of patients with a >20% decrease in CrCl was not different
between the two groups (IF: n 35 [25.9%], SF: n 41 [29.9%], P .46). However, the magnitude of decrease in CrCl
in patients with renal impairment was greater in patients treated with suprarenal fixation endografts (SF: 39%)
compared with those treated with infrarenal endografts (IF: 31%, P  .005). This greater degree of renal impairment
was not due to identifiable differences in preoperative risk factors, age, or baseline CrCl. No patients in these series
required dialysis.
Conclusions: Regardless the type of endograft used, there is a 10% decrease in CrCl in the first year after endovascular
aneurysm repair. Suprarenal fixation does not seem to increase the likelihood of postoperative renal impairment. Decline
in renal function over time after endovascular aortic repair is probably due to multiple factors, and measures known to be
effective in protecting kidneys should be considered for these patients. Long-term follow-up with measurement of CrCl,
along with renal imaging and regular blood pressure measurements, should be performed to detect possible late renal
dysfunction. Prospective studies comparing suprarenal versus infrarenal fixation are needed to confirm those results.
(J Vasc Surg 2005;41:926-30.)Successful endovascular aneurysm repair (EVAR) re-
quires a secure fixation of the proximal end of the aortic
endograft1 to prevent stent-graft migration and proximal
endoleak.2,3 Suprarenal endograft fixation has been pro-
posed to overcome the problem of an unfavorable or
suboptimal proximal neck o increase the number of
patients eligible for EVAR.4 However, concern persists
regarding the long-term effect on renal function when
struts of the uncovered stent cross the renal arteries
ostia.5 Many authors have reported their experience with
various follow-up periods without showing any signifi-
cant impact of suprarenal endograft fixation on renal
function.6-9 We reviewed our experience with suprarenal
endograft fixation compared with infrarenal endograft
fixation to determine whether there is a difference in
long-term renal function.
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926METHODS
Prospectively collected data in computerized databases of
277 patients treated by EVAR for nonruptured infrarenal
aortoiliac aneurysms (5 cm in diameter, between 4 and 5 cm
in diameter with a documented increase in diameter of 0.5 cm
in the past 6months, twice the diameter of the infrarenal neck,
or saccular, with infrarenal neck length of at least 1.5 cm) in
two institutions between January 2000 and June 2003 were
retrospectively reviewed. An endograft with infrarenal fixation
(Medtronic AneuRx) was used to treat 135 patients (Group
IF); 127patientswere treated in StanfordUniversityHospital,
Stanford, Calif and eight patients were treated in Henri-
Mondor University Hospital, Creteil, France. None of these
patients required dialysis because of preoperative chronic renal
failure. Two endografts with suprarenal fixation were used in
142 patients; 108 patients were treated with the Cook Zenith
endograft in Henri-Mondor University Hospital, and 34 pa-
tients were treated with the Medtronic Talent stent graft at
Stanford University Hospital. Of these 142 patients, five pa-
tients who required dialysis because of preoperative chronic
renal failure were excluded from further analysis. Of the re-
maining 137 patients (group SF), 106 patients were treated
with Cook Zenith and 31 patients were treated with
Medtronic Talent.
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aneurysm size, and risk factors as defined by the Society for
Vascular Surgery/American Association for Vascular Sur-
gery reporting standard,10 were obtained for all patients.
Renal function was evaluated by calculating the creati-
nine clearance (CrCl) using the Cockroft et al formula11:
CrCl  (140  age) (wt)/(72  Scr), age in years, wt
is absolute body weight in kilograms, Scr is serum creati-
nine in mg/100 mL.
Changes in renal function were evaluated by comparing
the preoperative and the latest available postoperative CrCl.
The observation period was defined as the interval from
surgery to the most recent follow-up examination.
Only patients with a 20% decrease in CrCl were
considered to have impaired renal function.8
Both institutions used the same methods for pretreat-
ing patients with renal insufficiency. The protocol used was
based on intravenous hydration for 48 hours preopera-
tively, and for patients with a creatinine clearance 40
mL/min, an antioxidant supplementation was added 2
days preoperatively. A similar postoperative surveillance
with contrast computed tomography (CT) scan (at 1, 3, 6,
and 12 months and annually thereafter) was performed for
all patients in both institutions.
Statistical analyses were performed using the 2 test and
Student’s t test. Multiple logistic regression analysis was
used to determine the factors independently associated
with postoperative renal impairment. Independent factors
that were included in multiple logistic regression modeling
were the type of fixation, age, sex, diameter of the abdom-
inal aortic aneurysm (AAA), preoperative risk factors, pre-
operative CrCl, and follow-up period. A Kaplan-Meier
life-table analysis of survival free from renal impairment,
using 20% decrease in CrCl as the event, was performed
in both groups, with a log-rank (Mantel-Cox) test to
compare them. Differences were deemed significant at P
.05.
RESULTS
There were no significant differences in patient age, sex,
aneurysm size, preoperative risk factors, or baseline CrCl
(IF: 69.3 mL/min, SF: 71.7 mL/min, P .4) between the
two groups (Table I). The amount of intraoperative con-
Table I. Patient demographic data, aneurysm size, and
preoperative risk factors
Infra  AneurX
(N  135)
Supra  Talent
 Zenith
(N 137) P
Age (y) 75.6 (48-100) 73.5 (47-89) .06
Sex (% male) 88.9 94.2 .12
Diameter AAA (mm) 54.3 (32-90) 56.1 (35-109) .17
Diabetes (%) 5.9 7.3 .65
Hypertension (%) 53.3 56.1 .72
AAA, Abdominal aortic aneurysm.trast media and the number of postoperative contrast-enhanced CT scans were similar in both groups (Table II).
Follow-up time was 12.2 months in both groups (range, 1
to 46 months), with similar variance. CrCl decreased sig-
nificantly during the follow-up period in both groups (IF:
69.3 mL/min to 61.7 mL/min, P  .01; SF: 71.7 mL/
min to 64.9 mL/min, P  .03). Postoperative CrCl (IF:
61.7 mL/min, SF: 64.9 mL/min, P .3), and rate of CrCl
decrease during the follow-up period (IF: 10.9 %, SF:
9.5 %, P  .2) were comparable between the two groups
(Table III).
The number of patients with a 20% decrease in CrCl
was not different between the two groups (IF: n  35
[25.9%], SF: n  41 [29.9%], P  .46). The magnitude of
decrease in CrCl in patients with renal impairment was
significantly greater in patients treated with suprarenal fix-
ation endografts (SF: 39%) compared with those treated
with infrarenal endografts (IF: 31%, P  .005). This
greater degree of renal impairment was not due to identi-
fiable differences in preoperative risk factors, age, sex, AAA
size, baseline CrCl, or follow-up length (Table IV).
The multiple logistic regression modeling showed that
site of fixation, age, sex, AAA size, preoperative risk factors,
and the amount of intra- or postoperative contrast media
were not associated with renal impairment, but the preop-
erative CrCl and the length of follow-up were indepen-
dently associated with renal impairment (Table V).
Kaplan-Meier life-table analysis of survival free from renal
impairment showed no difference between the two groups.
Mean survival was 31.1 months in group IF and 29.2 months
in group SF (P  .48 with log-rank test) (Fig 1). No patient in
this series required dialysis.
DISCUSSION
This study analyzed two large series of patients treated
with EVAR in two separate institutions during the same
period of time. Both institutions routinely treated patients
with infrarenal aneurysms using EVARwith the same range
of indications. This may explain why both series are very
comparable in terms of number of patients, age, sex, aneu-
rysm size, preoperative risk factors, baseline CrCl, and
follow-up period. All patients treated with the three most
commonly implanted commercial endograft devices were
reviewed at both institutions. The AneuRx stent graft is
now the most commonly implanted infrarenal device.12
The Zenith and the Talent devices represent the most
commonly implanted endografts with suprarenal fixa-
tion.13,14 These two endografts have similar systems of bare
metal transrenal fixation, with differences in uncovered
stent configuration regarding length and number of crowns
and barbs. It should be noted that stents used to support
endografts vary in construction, and their configuration
may influence their ability to affect renal function.15 At
Stanford, Talent endografts were used more likely for pa-
tients with shorter necks, but there were no strict anatomic
selection criteria. At Henri-Mondor, the Zenith endograft
was the only implanted device during this period.
Long-term CrCl was used as the main end point to
define the evolution of renal function. Many authors have
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only with measurements of CrCl.16 More sensitive tests can
be applied to determine the true effect of EVAR on renal
function, such as measurement of glomerular filtration rate
by renal scintigraphy,17 but such tests may not be practical
as routine investigations in large series of patients.18 Short-
term CrCl may be influenced by many factors during the
perioperative period such as the duration of the procedure,
anesthetic agents, nephrotoxic contrast media, and thus
may not be used as reliable evidence of definite renal
impairment.19 For this reason, we recorded the latest post-
operative CrCl at least 1 month after the procedure. We
noted an overall decrease in long-term CrCl of 10.2% (P
.0005), which is comparable with other series in the litera-
ture. We found no significant difference between patients
treated with infrarenal compared with those treated with
suprarenal fixation endovascular devices (10.9% vs 9.5%,
P  .2).20-22 The long-term decline in renal function after
EVAR was comparable with the decline after open repair of
aortic aneurysms reported by Greenberg et al.23 In our
Table II. Amount of intravenous contrast media during t
Infra  AneurX
(N  135)
Intraoperative contrast (mL) 137.5 (30-300)
Number of control CT scans 2.8 (0-7)
Postoperative contrast (mL) 466.9 (0-1155)
CT, Computed tomography.
Table III. Preoperative and postoperative CrCl and variat
Infra  Aneu
(N  135)
Preoperative CrCl (mL/min) 69.3 (15-148
Postoperative CrCl (mL/min) 61.7 (16-145
CrCl variation (mL/min) 7.6 (40 to 54) (P
CrCl variation rate (%) 10.9 (52 to
CrCl, Creatinine clearance.
Table IV. Patients with 20% decreased CrCl, demograp
evolution
Infra
(N
No. of patients with 20% decreased CrCl 35
Mean age (y) 73.7
Sex (% male)
Diameter AAA (mm) 53.1
Diabetes
Hypertension
Preoperative CrCl (mL/min) 74.7
Postoperative CrCl (mL/min) 51.6
CrCl Variation rate 30.9%
Follow-up period (mo) 15.4
AAA, Abdominal aortic aneurysm; CrCl, creatinine clearance.experience, long-term CrCl decreases of 6.4% after opensurgery. Only part of the decrease can be related to the
effect of age on CrCl, as Tiao et al24 have shown that after
the of age 75 years, patients lose about 2% of CrCl per year.
Table V. Logistic regression table for patients with
20% decrease in CrCl
P
Exp
(coefficient)
95%
lower
95%
upper
Fixation .2613 .682 .350 1.329
Age .1741 1.026 .989 1.064
Sex .3798 1.602 .560 4.583
Diameter AAA .7064 1.005 .978 1.033
Diabetes .6850 .782 .239 2.565
Hypertension .4265 1.255 .717 2.198
Intraoperative
contrast
.1043 1.004 .999 1.008
Postoperative
contrast
.5204 1.121 .791 1.589
Preoperative CrCl .0034 1.022 1.007 1.037
Follow-up period .0015 1.001 1.000 1.002
AAA, Abdominal aortic aneurysm; CrCl, creatinine clearance.
ocedure and follow-up period
Supra  Talent Zenith
(N  137) P
157.9 (40-600) .36
2.4 (0-6) .15
406.8 (0-990) .15
Supra  Talent  Zenith
(N  137) P
71.7 (28-156) .41
64.9 (20-163) .26
.01) 6.8 (95 to 61) (P  .02) .74
9.5 (70 to 91) .21
ata, aneurysm size, preoperative risk factors, and ClCr
neurX
35)
Supra  Talent
Zenith (N  137) P
9%) 41 (29.9%) .46
87) 75.2 (63-89) .37
90.2 .86
76) 56.6 (40-90) .20
% 7.3% .66
% 53.7% .65
119) 80.0 (32 to 135) .43
to 82) 48.8 (20 to 85) .46
2 to 21) 39% (70 to 20) .005
-40.2) 16.5 (1.3-40.1) .59he prions
rX
)
)
 0
59)hic d
 A
 1
(25.
(61-
91.4
(34-
5.7
54.3
(35-
(24
(5
(1.2Regardless the type of endograft used, there is a significant
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cannot be only explained by the effect of age on renal
function.
We considered a 20% decrease in CrCl to be related
to physiologic daily variations without clinical conse-
quences. The choice of a 20% decrease in CrCl after
EVAR as a definition of postoperative renal impairment
appears clinically relevant.8,25,26 The number of patients
with a 20% decrease in CrCl is the second end point of
this study.We found no difference between Supra and Infra
renal endografts (29.9% vs 25.9%, P  .46) and no associ-
ation between the fixation site and renal impairment in a
multiple logistic regression modeling. These results are
confirmed by a Kaplan-Meier life-table analysis of survival
free from renal impairment (Fig 1). Suprarenal fixation
does not seem to increase the number of patients with renal
impairment after aortic endografting.
There were no identifiable differences in preoperative
risk factors, age, sex, or baseline CrCl in this subgroup
(Table III). However, our study showed that a higher
preoperative CrCl appears to be associated with a greater
magnitude of postoperative renal dysfunction,9 suggesting
that patients with poorer preoperative renal function were
less likely to have worsening postoperative renal function
(Table IV). Although we did not show any statistical sig-
nificance, this could be explained by the efficiency of peri-
operative protocols of hydration and the minimal use of
contrast media during and after the procedure, with limi-
tation of postoperative use of contrast in imaging examina-
tions, in patients with preoperative renal dysfunction.27
These results suggest that when physicians are aware of
preoperative renal failure, they take measures to protect the
patient from renal function worsening. Such strategies
should be considered for all patients undergoing aortic
aneurysm repair, which may reduce the effect of aortic stent
grafting on renal function. However, this might still be
difficult to apply to patients included in clinical trials in
which they are subjected to a more rigorous surveillance
Kaplan-Meier life-table analysis of survival free of renal impairment in
the two groups. Log-rank test: P .48.protocol including frequent contrast-enhanced CT scans.The magnitude of decrease of CrCl in patients who
experienced significant renal impairment was significantly
greater for patients treated with suprarenal fixation en-
dografts (SF: 39%) compared with those treated with
infrarenal endografts (IF: 31%, P  .005). These results
do not take into account the inherent inaccuracy of the
Cockcroft formula (correlation coefficient  .83).11 In the
group of patients who had 20% decrease in CrCl, the
infrarenal fixation group had a lower mean age than the
suprarenal fixation group, and this difference may have also
affected the calculations of the mean CrCl for each group.
Patients who experienced the greatest postoperative renal
impairment may have had renal infarctions, but the exact
cause of decline in renal function was not clearly defined in
most patients. However, significant renal parenchymal tis-
sue loss28 or renal artery stenosis can occur without a
significant effect on CrCl.7,29,30 The exclusion of accessory
renal arteries secondary to endograft deployment does not
appear to be responsible for renal function impairment if
the parenchyma loss is 25%.31 In previous studies,32-34
the small number of diagnosed renal infarctions that oc-
curred was clinically benign. No patient in these series
required dialysis or had any symptoms of renal dysfunction.
One limitation of our study is that we were unable to
accurately report on postoperative changes in blood pres-
sure (renovascular hypertension) that might have resulted
from suprarenal stenting. Two series in the literature re-
ported no significant change in average recorded blood
pressure at 6 and 12 months after suprarenal fixation.3,35
We believe that patients with significant renal impairment
should be followed more closely with regular CrCl mea-
surements; adapted imaging such as noncontrast-enhanced
CT scans, infrarenal color duplex examinations,19 and mag-
netic resonance angiography; and screening of renovascular
hypertension. Close follow-up will help to detect possible
late renal dysfunction and to prevent its clinical symptoms
such as renovascular hypertension.
In conclusion, regardless the type of endograft used,
there is approximately a 10% decrease in CrCl in the first
year after EVAR. Suprarenal fixation does not seem to
increase the likelihood of postoperative renal impairment.
Decline in renal function over time after EVAR is probably
due to multiple factors, and measures known to be effective
in protecting kidneys should be considered for patients
treated with EVAR. Long-term follow-up with measure-
ment of CrCl, along with renal imaging and regular blood
pressure measurements, should be performed to detect
possible late renal dysfunction. Prospective studies compar-
ing suprarenal versus infrarenal fixation are needed to con-
firm those results.
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